Oncotarget

BUFFALO, NY - March 17, 2025 – Impact Journals (Oncotarget’s publisher), is pleased to announce its participation as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2025. The meeting is scheduled for April 25-30, 2025, at the McCormick Place Convention Center in Chicago, Illinois. The 2025 AACR Annual Meeting's central theme, "Unifying Cancer Science and Medicine: A Continuum of Innovation for Impact," highlights major breakthroughs and innovative developments transforming cancer research. Oncotarget aligns directly with this vision, being always committed to rapidly publishing and disseminating impactful research findings across diverse areas of cancer science and thus advancing cancer treatment and patient care. Conference attendees are warmly invited to visit Booth 2815 to meet members of the Oncotarget, discover notable recent publications, and discuss collaborative opportunities. Oncotarget, assisted by its publisher Impact Journals, remains focused on accelerating the sharing of crucial oncology research, fostering innovation, and maintaining excellence in cancer research. About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Dr. Wade T. Iams, a researcher from the Vanderbilt Ingram Cancer Society Center, dives into the complexities of lung cancer treatment. He discusses a groundbreaking case where a patient developed resistance to lorlatinib due to a rare genetic alteration, RUFY1-RET. This revelation emphasizes the critical role of advanced genetic testing and the necessity for personalized cancer treatments. As cancer evolves, understanding resistance mechanisms becomes vital for effective precision oncology.

New insights challenge traditional approaches to breast cancer treatment. It’s revealed that some early-stage diagnoses may not require immediate surgery, thanks to findings from the COMET trial. This research suggests that active monitoring could be a viable alternative for many patients. The discussion emphasizes the importance of identifying precise biomarkers to ensure only those who truly need intervention receive it. It raises critical questions about the effectiveness of current screening programs in discerning dangerous cancers from those that may never pose a threat.

Discover the intriguing link between environmental factors and cancer risk. Experts discuss how pollution, diet, and chronic stress can trigger genetic changes leading to cancer. It's revealed that nearly everyone is exposed to harmful elements daily, with over 99% of the population breathing polluted air. The dangers of processed foods, tobacco smoke, and UV radiation are highlighted, showcasing how these factors can damage DNA and disrupt the body's repair mechanisms. Understanding these connections could be key in cancer prevention and public health initiatives.

Researchers delve into a groundbreaking study on engineered TIMP molecules that could slow the aggressive spread of glioblastoma, a challenging brain cancer. They reveal how natural inhibitors can effectively block cancer cell migration while preserving healthy tissue. By focusing on TIMP-1, TIMP-3, and their engineered variants, the potential to improve treatment outcomes for this deadly disease emerges. This innovative approach may revolutionize cancer therapy and open new avenues in the fight against glioblastoma.

Mailson Alves Lopes, a researcher from the University of Brasília, discusses groundbreaking findings on the use of cell-free DNA (cfDNA) to monitor colorectal cancer surgery success. He explains how real-time blood tests could reveal tumor removal effectiveness and predict patient outcomes. Lopes emphasizes that by tracking cfDNA levels before, during, and after surgery, clinicians may enhance postoperative care and detect cancer recurrence earlier. This innovative approach could revolutionize how colorectal cancer patients are monitored and treated.

Fred Bunz, a renowned researcher from the Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins University School of Medicine, delves into the pivotal role of the p53 protein in cancer biology. He discusses groundbreaking research revealing how restoring p53 functionality can slow cancer cell growth and increase sensitivity to radiation therapy. Bunz emphasizes the importance of targeting p53 mutations, as they contribute to treatment resistance, offering a hopeful path for developing new cancer therapies.

Researchers delve into a groundbreaking study on a special membrane designed for healing chemotherapy-induced mouth ulcers. They explore how electrospun PLGA membranes, especially those infused with the body's own healing cells, can speed up recovery and reduce inflammation. This innovative approach could transform treatment for cancer patients struggling with painful oral mucositis, a common side effect of chemotherapy. The findings provide a glimmer of hope for enhancing the quality of life during cancer treatment.

Delve into a groundbreaking study on maintaining treatment for metastatic colorectal cancer. Researchers highlight the promising combination of Panitumumab and low-dose Capecitabine, showing potential benefits in survival rates. This innovative regimen appears well-tolerated, offering new hope for patients with wild-type KRAS mCRC. Explore the challenges of standard treatments and the quest for lower-intensity options that can keep cancer under control without overwhelming toxicity.

Delve into the fascinating world of osteosarcoma and the gene SETDB1, which is making waves in cancer research. Discover how SETDB1 amplification contributes to the aggressive nature of this bone cancer, especially in young people. The discussion highlights innovative strategies that could target SETDB1 to improve treatment outcomes. With insights from recent studies, listeners will learn how this gene helps tumors evade the immune system and resist therapy, paving the way for possible breakthroughs in combating osteosarcoma.